This article was originally published in The Tan Sheet
SmithKline Beecham tells FDA that OTC manufacturers should be allowed to start a heading or subheading on one column of a "Drug Facts" box and continue onto the next column by repeating the heading or subheading and adding "continued" in parentheses. In a Jan. 28 letter discussing FDA's draft guidance on the use of a column format for required "Drug Facts" information, SmithKline says its suggestion would replace the need for the "Drug Facts (continued)" statement at the top of subsequent columns, "but still indicate the flow of the text to the consumer." CHPA and CTFA also have commented on the FDA guidance (1"The Tan Sheet" Feb. 14, p. 8)
You may also be interested in...
The use of different size columns for multiple "Drug Facts" boxes on OTC labels would give manufacturers greater flexibility to include graphics within the box, industry trade groups tell FDA.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning